For example, the addition of MEK to KRAS G12C inhibition, as seen with the combination of trametinib and sotorasib, has exhibited anti-tumor efficacy and an acceptable safety profile in advanced KRAS G12C-mutated solid tumors [87]. Here, KRAS is linked to neoplasm.